Roche isn’t done lining up new collaborations in the hot field of drugging RNA. Here’s one more
Roche has a big appetite for all things involving drugging RNA. And they just ordered a fresh helping to see if they can start to satiate the hunger.
Last April Roche BD chief James Sabry signed off on a $190 million upfront to get started on a collaboration with Arrakis, the startup from Mike Gilman that created one of the pioneers in the space. That followed a deal with Bill Haney’s Skyhawk, another upstart looking to drug the undruggable by way of RNA. And today it’s Ribometrix’s turn, which snares a $25 million cash down payment from Genentech and more than a billion dollars in milestones for big-picture success.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,600+ biopharma pros reading Endpoints daily — and it's free.